P Bech 1 , P Boyer , J-M Germain , K Padmanabhan , V Haudiquet , B Pitrosky , K A Tourian . Show Affiliations »
Abstract
Show RCT »
Hide RCT «
INTRODUCTION: This retrospective analysis compared sensitivity to change on the 17-item and 6-item Hamilton Rating Scales For Depression (HAM-D (17) and HAM-D (6 ), respectively) in relation to antidepressant dose and baseline depression severity. METHODS: Data were derived from 6 randomized, double-blind, placebo -controlled, 8-week trials of fixed-dose desvenlafaxine (50, 100, 200 or 400 mg/d) for major depressive disorder . HAM-D (17) and HAM-D (6 ) effect sizes were assessed. RESULTS: HAM-D (17 ) effect sizes were negative (favoured placebo ) for higher desvenlafaxine doses (200-400 mg/d) at week 1, but were positive for all doses after week 2, with no clear dose-response pattern. However, HAM-D (6) effect sizes were positive for all doses at all weeks. Effect sizes were consistently greater for HAM-D (6) vs. HAM-D (17 ), regardless of time spent under therapy. Effect sizes were greater for HAM-D (6) vs. HAM-D (17 ) for all desvenlafaxine doses among patients with baseline HAM-D (17 ) <25, but not among patients with baseline HAM-D (17 ) ≥ 25. DISCUSSION: The HAM-D (6) demonstrated greater sensitivity to change and robustness than the HAM-D (17 ), supporting the greater homogeneity of the HAM-D (6). © Georg Thieme Verlag KG Stuttgart · New York.
RCT Entities: Population
Interventions
Outcomes
INTRODUCTION: This retrospective analysis compared sensitivity to change on the 17-item and 6-item Hamilton Rating Scales For Depression (HAM-D (17) and HAM-D (6), respectively) in relation to antidepressant dose and baseline depression severity. METHODS: Data were derived from 6 randomized, double-blind, placebo-controlled, 8-week trials of fixed-dose desvenlafaxine (50, 100, 200 or 400 mg/d) for major depressive disorder . HAM-D (17) and HAM-D (6) effect sizes were assessed. RESULTS: HAM-D (17) effect sizes were negative (favoured placebo) for higher desvenlafaxine doses (200-400 mg/d) at week 1, but were positive for all doses after week 2, with no clear dose-response pattern. However, HAM-D (6) effect sizes were positive for all doses at all weeks. Effect sizes were consistently greater for HAM-D (6) vs. HAM-D (17), regardless of time spent under therapy. Effect sizes were greater for HAM-D (6) vs. HAM-D (17) for all desvenlafaxine doses among patients with baseline HAM-D (17) <25, but not among patients with baseline HAM-D (17) ≥ 25. DISCUSSION: The HAM-D (6) demonstrated greater sensitivity to change and robustness than the HAM-D (17), supporting the greater homogeneity of the HAM-D (6). © Georg Thieme Verlag KG Stuttgart · New York.
Entities: Chemical
Disease
Species
Mesh: See more »
Substances: See more »
Year: 2010
PMID: 20830664 DOI: 10.1055/s-0030-1263173
Source DB: PubMed Journal: Pharmacopsychiatry ISSN: 0176-3679 Impact factor: 5.788